S-布洛芬
| 中文名称 | S-布洛芬 |
|---|---|
| 中文同义词 | S-布洛芬;S-布洛芬 5G;雷美替胺杂质G;(S)-(+)-布洛芬, 95+%;(S)-(+)-布洛芬 [(S)-(+)-2-(4-异丁基苯)丙酸];(2S)-2-(4-异丁基苯)丙酸;(S)-(+)-布洛芬/2-(4-异丁基苯基)丙酸;(S)-2-(4-异丁基苯基)丙酸 |
| 英文名称 | (S)-(+)-Ibuprofen |
| 英文同义词 | (S)-(+)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID;(S)-(+)-4-ISOBUTYL-ALPHA-METHYLPHENYLACETIC ACID;(S)-(+)-IBUPROFEN;(2s)-2-[4-(2-methylpropyl)phenyl]propionic acid;(S)-(+)-Ibuprofen ReagentPlus(R), 99%;(S)-2-(4-Isobutylphenyl)propanoic acid, 95+%;(S)-((addition))-Ibuprofen;(S)-(+)-4-Isobutyl-a-methylphenylacetic acid |
| CAS号 | 51146-56-6 |
| 分子式 | C13H18O2 |
| 分子量 | 206.28 |
| EINECS号 | 610-620-9 |
| 相关类别 | 医药中间体;羧酸;小分子抑制剂;医药原料;神经系统用药;解热镇痛药;医药与生物化工;有机砌块;化合物：原料药;原料药;医药 解热镇痛;对照品-杂质对照品;医药原料药-科研原料;医用原料;医用原料;Chiral Reagents;Chiral Compound;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;AMIDATE;原料;杂质对照品;日用化学品;医药原料药;化学试剂;常规产品 |
| Mol文件 | 51146-56-6.mol |
| 结构式 |  |
S-布洛芬 性质
| 熔点 | 49-53 °C(lit.) |
|---|---|
| 比旋光度 | 57 º (c=2, EtOH) |
| 沸点 | 285.14°C (rough estimate) |
| 密度 | 1.0364 (rough estimate) |
| 折射率 | 59 ° (C=2, EtOH) |
| 闪点 | >230 °F |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 在45%(w/v)aq2-羟丙基-β-环糊精溶解度为：1.5 mg/mL |
| 酸度系数(pKa) | 4.41±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色 |
| 旋光性 (optical activity) | [α]20/D +59°, c = 2 in ethanol |
| 水溶解性 | insoluble |
| BRN | 3590022 |
| 稳定性 | 稳定的。与强氧化剂不相容。 |
| InChIKey | HEFNNWSXXWATRW-JTQLQIEISA-N |
| CAS 数据库 | 51146-56-6(CAS DataBase Reference) |
|
COX-1 2.1 μM (IC 50 ) |
COX-2 1.6 μM (IC 50 ) |
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent.
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 µM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1.
(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.
(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC
50
of 61.7 μM.
Cell Proliferation Assay
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 0 µM, 200 µM, 400 µM, 600 µM, 700 µM, 800 µM, 900 µM, and 1000 µM |
| Incubation Time: | 8 days |
| Result: | Reduced concentration dependently cell survival in both cell lines to a similar extent. |
Cell Cycle Analysis
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM |
| Incubation Time: | 24 hours (HCT-15) or 20 hours (HCA-7) |
| Result: | Caused a G0/G1 phase block. |
Apoptosis Analysis
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM |
| Incubation Time: | 72 hours |
| Result: | Induced cell apoptosis. |
Western Blot Analysis
| Cell Line: | HCT-15 and HCA-7 cells |
| Concentration: | 900 µM |
| Incubation Time: | 4 hours, 8 hours, 16 hours, 24 hours, 32 hours, 48 hours and 72 hours |
| Result: | Decreased levels of Cyclin D1 protein. |
(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.
| Animal Model: | NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells |
| Dosage: | 15 mg/kg/day |
| Administration: | Intraperitoneal injection; five days a week; for 4 weeks |
| Result: | Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice. |
| 提供商 | 语言 |
|---|---|
|
英文
|
|
|
英文
|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-78131A | S-布洛芬 (S)-(+)-Ibuprofen | 51146-56-6 | 500mg | 350元 |
| 2024/01/25 | HY-78131A | S-布洛芬 (S)-(+)-Ibuprofen | 51146-56-6 | 10mM * 1mLin DMSO | 385元 |